Stefanie Schulz

Stefanie Schulz

Auto-generated profile, based on publicly available information

Stefanie Schulz

Deutsches Herzzentrum München, Technische Universität, Munich, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in The Lancet
Verified
Journal Article
Closed access
RBRobert A Byrne
Robert A Byrne
FNFranz-Josef Neumann
Franz-Josef Neumann
JMJulinda Mehilli
Julinda Mehilli
SPSusanne Pinieck
Susanne Pinieck
BWBritta Wolff
Britta Wolff
AKAdnan Kastrati
Adnan Kastrati

1 April 2015 in JACC
Verified
Journal Article
Closed access
KFKatrin A. Fiedler
Katrin A. Fiedler
MMMichael Maeng
Michael Maeng
JMJulinda Mehilli
Julinda Mehilli
SSStefanie Schulz-Schüpke
Stefanie Schulz-Schüpke
RBRobert A. Byrne
Robert A. Byrne
NSNikolaus Sarafoff
Nikolaus Sarafoff

23 January 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SSStefanie Schulz-Schüpke
Stefanie Schulz-Schüpke
RBRobert A Byrne
Robert A Byrne
JBJurrien M Ten Berg
Jurrien M Ten Berg
FNFranz-Josef Neumann
Franz-Josef Neumann
YHYaling Han
Yaling Han
IIIntracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators
Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators
In patients receiving aspirin, the optimal duration of clopidogrel therapy after drug-eluting stent (DES) implantation remains unclear. This multicentre, randomized, double-blind, placebo-controlled trial tested the hypothesis that in patients undergoing DES implantation, 6 months of clopidogrel is non-inferior to 12 months in terms of clinical outcomes. At 6 months after DES implantation, patients on clopidogrel were randomly assigned to either a 6-month period of placebo or an additional 6-month period of clopidogrel. The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, and thrombolysis in myocardial infarction major bleeding at 9 months after randomization. Owing to slow recruitment and low event rates, the trial was stopped prematurely after enrolment of 4005 of 6000 planned patients. Of 4000 patients included in the final analysis, 1997 received 6 months of clopidogrel and 2003 received 12 months. The primary endpoint occurred in 29 patients (1.5%) assigned to 6 months of clopidogrel and 32 patients (1.6%) assigned to 12 months, observed difference −0.1%, upper limit of one-sided 95% confidence interval (CI) 0.5%, limit of non-inferiority 2%, Pfornoninferiority <0.001. Stent thrombosis was observed in five patients (0.3%) assigned to 6 months of clopidogrel and three patients (0.2%) assigned to 12 months; hazard ratio (HR) 1.66, 95% CI: 0.40–6.96, P = 0.49. Thrombolysis in myocardial infarction major bleeding was observed in 4 patients (0.2%) assigned to 6 months clopidogrel and 5 patients (0.3%) assigned to 12 months; HR 0.80, 95% CI: 0.21–2.98, P = 0.74. In the present trial, characterized by low event rates, we did not observe a significant difference in net clinical outcome between 6 and 12 months of clopidogrel therapy after DES implantation. However, the results of the trial must be considered in view of its premature termination and lower than expected event rates. The trial is registered with ClinicalTrials.gov, Identifier: NCT00661206.

1 December 2013 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
TTTomohisa Tada
Tomohisa Tada
RBRobert A. Byrne
Robert A. Byrne
ISIva Simunovic
Iva Simunovic
LKLamin A. King
Lamin A. King
SCSalvatore Cassese
Salvatore Cassese
AKAdnan Kastrati
Adnan Kastrati

14 August 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AKAdnan Kastrati
Adnan Kastrati
FNFranz-Josef Neumann
Franz-Josef Neumann
JMJulinda Mehilli
Julinda Mehilli
RBRobert A. Byrne
Robert A. Byrne
RIRaisuke Iijima
Raisuke Iijima
ASAlbert Schömig
Albert Schömig
Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with clopidogrel is unknown. We enrolled 4570 patients with stable or unstable angina (with normal levels of troponin T and creatine kinase MB) who were undergoing PCI after pretreatment with a 600-mg dose of clopidogrel at least 2 hours before the procedure; 2289 patients were randomly assigned in a double-blind manner to receive bivalirudin, and 2281 to receive unfractionated heparin. The primary end point was the composite of death, myocardial infarction, urgent target-vessel revascularization due to myocardial ischemia within 30 days after randomization, or major bleeding during the index hospitalization (with a net clinical benefit defined as a reduction in the incidence of the end point). The secondary end point was the composite of death, myocardial infarction, or urgent target-vessel revascularization. The incidence of the primary end point was 8.3% (190 patients) in the bivalirudin group as compared with 8.7% (199 patients) in the unfractionated-heparin group (relative risk, 0.94; 95% confidence interval [CI], 0.77 to 1.15; P=0.57). The secondary end point occurred in 134 patients (5.9%) in the bivalirudin group and 115 patients (5.0%) in the unfractionated-heparin group (relative risk, 1.16; 95% CI, 0.91 to 1.49; P=0.23). The incidence of major bleeding was 3.1% (70 patients) in the bivalirudin group and 4.6% (104 patients) in the unfractionated-heparin group (relative risk, 0.66; 95% CI, 0.49 to 0.90; P=0.008). In patients with stable and unstable angina who underwent PCI after pretreatment with clopidogrel, bivalirudin did not provide a net clinical benefit (i.e., it did not reduce the incidence of the composite end point of death, myocardial infarction, urgent target-vessel revascularization, or major bleeding) as compared with unfractionated heparin, but it did significantly reduce the incidence of major bleeding. (ClinicalTrials.gov number, NCT00262054.)

24 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AKAdnan Kastrati
Adnan Kastrati
FNFranz-Josef Neumann
Franz-Josef Neumann
SSStefanie Schulz
Stefanie Schulz
SMSteffen Massberg
Steffen Massberg
RBRobert A Byrne
Robert A Byrne
IIISAR-REACT 4 Trial Investigators
ISAR-REACT 4 Trial Investigators
The combination of glycoprotein IIb/IIIa inhibitors and heparin has not been compared with bivalirudin in studies specifically involving patients with non–ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). We compared the two treatments in this patient population. Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non–ST-segment elevation myocardial infarction to receive abciximab plus unfractionated heparin (861 patients) or bivalirudin (860 patients). The study tested the hypothesis that abciximab and heparin would be superior to bivalirudin with respect to the primary composite end point of death, large recurrent myocardial infarction, urgent target-vessel revascularization, or major bleeding within 30 days. Secondary end points included the composite of death, any recurrent myocardial infarction, or urgent target-vessel revascularization (efficacy end point) and major bleeding (safety end point) within 30 days. The primary end point occurred in 10.9% of the patients in the abciximab group (94 patients) and in 11.0% in the bivalirudin group (95 patients) (relative risk with abciximab, 0.99; 95% confidence interval [CI], 0.74 to 1.32; P=0.94). Death, any recurrent myocardial infarction, or urgent target-vessel revascularization occurred in 12.8% of the patients in the abciximab group (110 patients) and in 13.4% in the bivalirudin group (115 patients) (relative risk, 0.96; 95% CI, 0.74 to 1.25; P=0.76). Major bleeding occurred in 4.6% of the patients in the abciximab group (40 patients) as compared with 2.6% in the bivalirudin group (22 patients) (relative risk, 1.84; 95% CI, 1.10 to 3.07; P=0.02). Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary end point and increased the risk of bleeding among patients with non–ST-segment elevation myocardial infarction who were undergoing PCI. (Funded by Nycomed Pharma and others; ISAR-REACT 4 ClinicalTrials.gov number, NCT00373451.)